Brey Robin L
University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7883, USA.
J Thromb Thrombolysis. 2005 Oct;20(2):105-12. doi: 10.1007/s11239-005-3204-6.
Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss.
The literature pertaining to stroke associated with antiphospholipid antibodies, with emphasis on stroke in young adults, was reviewed.
Antiphospholipid antibodies are an independent risk factor for stroke in young adults in five of six studies. Multiple antiphospholipid specificities or the Lupus Anticoagulant were tested in addition to anticardiolipin antibody in these studies. In the single study that found no increased risk for stroke, only anticardiolipin antibody was tested. Only one of these studies evaluated for risk of recurrent stroke in young adults with antiphospholipid antibodies and found it to be increased. No treatment trials have been conducted in young adults with antiphospholipid antibodies and stroke. In the single treatment trial comparing aspirin and low-INR producing doses of warfarin to prevent recurrent stroke, both were found to be equally effective.
Antiphospholipid antibodies, particularly Lupus Anticoagulant, is an independent risk factor for first and possibly recurrent ischemic stroke in young adults. The best therapeutic strategy for preventing antiphospholipid antibody-associated recurrent stroke is not clear.
抗磷脂抗体与一种包括血栓形成和不明原因反复流产的临床综合征相关。
回顾了与抗磷脂抗体相关的中风文献，重点关注年轻成年人的中风情况。
在六项研究中的五项里，抗磷脂抗体是年轻成年人中风的独立危险因素。在这些研究中，除了检测抗心磷脂抗体外，还检测了多种抗磷脂特异性抗体或狼疮抗凝物。在唯一一项未发现中风风险增加的研究中，仅检测了抗心磷脂抗体。这些研究中只有一项评估了抗磷脂抗体阳性的年轻成年人复发性中风的风险，发现风险增加。尚未针对抗磷脂抗体阳性且中风的年轻成年人进行治疗试验。在一项比较阿司匹林和低国际标准化比值（INR）的华法林剂量预防复发性中风的单一治疗试验中，发现两者同样有效。
抗磷脂抗体，尤其是狼疮抗凝物，是年轻成年人首次及可能的复发性缺血性中风的独立危险因素。预防抗磷脂抗体相关复发性中风的最佳治疗策略尚不清楚。
Zotero 插件